H. Lassmann, W. Brück, and C. F. Lucchinetti, The immunopathology of multiple sclerosis: an overview, Brain Pathol, vol.17, issue.2, pp.210-218, 2007.

J. Correale, M. I. Gaitán, M. C. Ysrraelit, and M. P. Fiol, Progressive multiple sclerosis: from pathogenic mechanisms to treatment, Brain, p.258, 2016.

S. Vukusic and C. Confavreux, Primary and secondary progressive multiple sclerosis

, J Neurol Sci, vol.206, issue.2, pp.153-158, 2003.

D. A. Cottrell, M. Kremenchutzky, G. P. Rice, and W. J. Koopman,

J. , The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis, Brain J Neurol, 1999.

H. Tremlett, D. Paty, and V. Devonshire, The natural history of primary progressive MS in British Columbia, Canada. Neurology, vol.65, issue.12, pp.1919-1923, 2005.

J. Howard, S. Trevick, and D. S. Younger, Epidemiology of Multiple Sclerosis, Neurol Clin, vol.34, issue.4, pp.919-958, 2016.

A. Alonso and M. A. Hernan, Temporal trends in the incidence of multiple sclerosis: A systematic review, Neurology, vol.71, issue.2, pp.129-164, 2008.

F. D. Lublin and S. C. Reingold, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, 1996.

K. A. Mckay, S. Jahanfar, T. Duggan, S. Tkachuk, and H. Tremlett, Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review, NeuroToxicology, vol.61, pp.189-212, 2017.

L. F. Barcellos, S. Sawcer, P. P. Ramsay, S. E. Baranzini, G. Thomson et al.,

, Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis, Hum Mol Genet, 2006.

, Sep, vol.15, issue.18, pp.2813-2837

J. Correale and M. I. Gaitán, Multiple sclerosis and environmental factors: the role of vitamin D, parasites, and Epstein-Barr virus infection, Acta Neurol Scand, vol.132, pp.46-55, 2015.

S. M. Kimball, M. R. Ursell, P. O'connor, and R. Vieth, Safety of vitamin D3 in adults with multiple sclerosis, Am J Clin Nutr, vol.86, issue.3, pp.645-651, 2007.

J. Correale, M. C. Ysrraelit, and M. I. Gaitan, Immunomodulatory effects of Vitamin D in multiple sclerosis, Brain, vol.132, issue.5, pp.1146-60, 2009.

A. Ascherio and K. L. Munger, Epstein-Barr Virus Infection and Multiple Sclerosis: A Review, J Neuroimmune Pharmacol, vol.5, issue.3, pp.271-278, 2010.

K. Munger, L. Levin, E. O'reilly, K. Falk, and A. Ascherio, Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel, Mult Scler J, vol.17, issue.10, pp.1185-93, 2011.

C. Yea, R. Tellier, P. Chong, G. Westmacott, R. A. Marrie et al.,

, Barr virus in oral shedding of children with multiple sclerosis, Neurology, vol.81, issue.16, pp.1392-1399, 2013.

R. A. Farrell, A. D. Wall, G. R. Clark, D. A. Fisniku, L. Swanton et al., Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI, Neurology, vol.73, issue.1, pp.32-38, 2009.

M. A. Hernán, S. S. Jick, G. Logroscino, M. J. Olek, A. Ascherio et al., Smoking does not influence disability accumulation in primary progressive multiple sclerosis, Eur J Neurol, vol.128, issue.6, pp.1461-1466, 2005.

C. Confavreux, S. Vukusic, F. D. Lublin, S. C. Reingold, J. A. Cohen et al., Natural history of multiple sclerosis: a unifying concept, Brain, vol.129, issue.3, pp.606-616, 2006.

, Defining the clinical course of multiple sclerosis: The 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014.

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-or et al.,

, Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, N Engl J Med, 2017.

J. S. Wolinsky, P. A. Narayana, P. O'connor, P. K. Coyle, C. Ford et al.,

K. Hawker, P. O'connor, M. S. Freedman, P. A. Calabresi, J. Antel et al., Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann Neurol, vol.61, issue.1, pp.14-24, 2007.

F. Lublin, D. H. Miller, M. S. Freedman, B. Cree, J. S. Wolinsky et al., Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, pp.460-71, 2009.

A. Tourbah, C. Lebrun-frenay, G. Edan, M. Clanet, C. Papeix et al., Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, vol.387, pp.1075-84, 2016.

E. Leray, J. Yaouanq, L. Page, E. Coustans, M. Laplaud et al., MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study, Mult Scler J, vol.22, issue.13, pp.1900-1913, 2010.

M. Debouverie, S. Pittion-vouyovitch, S. Louis, and F. Guillemin,

. Group, Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, 2008.

K. E. Harding, M. Wardle, P. Moore, V. Tomassini, T. Pickersgill et al., Modelling the natural history of primary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 2015.

C. Confavreux, S. Vukusic, T. Moreau, P. Adeleine, M. Kremenchutzky et al., The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease, Poser CM, vol.343, pp.584-94, 2000.

, New diagnostic criteria for multiple sclerosis: Guidelines for research protocols, Ann Neurol, vol.13, issue.3, pp.227-258, 1983.

C. H. Polman, S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen et al.,

, Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, Ann Neurol, vol.69, issue.2, pp.292-302, 2011.

J. F. Kurtzke, S. R. Choi, O. W. Howell, D. Carassiti, R. Magliozzi et al., Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1444, 1983.

, Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis, Brain, vol.135, issue.10, pp.2925-2962, 2012.

M. Koch, E. Kingwell, P. Rieckmann, and H. Tremlett, The natural history of primary progressive multiple sclerosis, Neurology, vol.73, issue.23, pp.1996-2002, 2009.

P. Soldan, M. M. Novotna, M. , A. Zeid, N. Kale et al.,

, Relapses and disability accumulation in progressive multiple sclerosis, Neurology, 2015.

Z. Khaleeli, O. Ciccarelli, F. Manfredonia, F. Barkhof, B. Brochet et al., Sastre-Garriga J TA. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data, Ann Neurol, vol.63, issue.6, pp.633-638, 2005.

, Long-term disability progression in primary progressive multiple sclerosis: a 15-year study, Brain, vol.140, issue.11, pp.2814-2823, 2017.

J. Stellmann, A. Neuhaus, C. Lederer, M. Daumer, and C. Heesen, Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review. Villoslada P, editor, PLoS ONE, vol.9, issue.3, p.92761, 2014.

A. Signori, G. Izquierdo, A. Lugaresi, R. Hupperts, F. Grand'maison et al.,

, Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis, Mult Scler J, vol.24, issue.5, pp.642-652, 2018.